Feed DXR
DX

Daxor Corporation

DXR · NASDAQ

$11.45 +1.78% (+$0.20)
1M +17.20%
Market Cap $67.9M
P/E Ratio 7.40x
Div. Yield -
ROE 21.69%

Bulios Fair Price

$6.93

39.5% downside

Current Price

$11.45

Undervalued Fair Value Overvalued

According to Bulios Fair Price, DXR is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
4/9
Valuation
86 /100
Cheap
P/E 7.40x
PEG 0.00x
EV/EBITDA 7.40x
Growth
100 /100
Growing
EPS growth 45.29%
Book val. growth 16.57%
Rev. growth N/A
Profitability
65 /100
Moderate
Gross margin 37.49%
FCF margin 120.06%
Net margin 1,821.48%
Quality
85 /100
Excellent
ROIC 19.96%
Asset turnover 0.01x
ROE 21.69%
Debt
100 /100
Low
Debt/Equity 0.00x
Net debt/EBITDA 0.01x
Int. coverage 575.44x
Stability
16 /100
Unstable
Beta 0.26x
Profitable years 5
Rev. volatility 5,758.58%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about DXR
Online

Sector

Healthcare

Industry

Medical - Instruments & Supplies

CEO

Michael Richard Feldschuh

Employees

37

Headquarters

Oak Ridge

Upcoming events

10 MAR

Earnings

Upcoming earnings report

170d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.